Similar articles

• Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.

  [No authors listed] [No authors listed] J Clin Oncol. 1991 Sep;9(9):1668-74. doi: 10.1200/JCO.1991.9.9.1668. J Clin Oncol. 1991. PMID: 1831495
• A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma.

  Bertelsen K, Jakobsen A, Andersen JE, Ahrons S, Pedersen PH, Kiaer H, Arffmann E, Bichel P, Boestofte E, Strøyer I, et al. Bertelsen K, et al. Gynecol Oncol. 1987 Oct;28(2):161-9. doi: 10.1016/0090-8258(87)90210-1. Gynecol Oncol. 1987. PMID: 3311924 Clinical Trial.
• Re: randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

  Atkins CD. Atkins CD. J Natl Cancer Inst. 2000 Sep 6;92(17):1446-7. doi: 10.1093/jnci/92.17.1446. J Natl Cancer Inst. 2000. PMID: 10974091 No abstract available.
• Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.

  Thigpen T, Vance R, Puneky L, Khansur T. Thigpen T, et al. Gynecol Oncol. 1994 Dec;55(3 Pt 2):S97-107. doi: 10.1006/gyno.1994.1347. Gynecol Oncol. 1994. PMID: 7835816 Review.
• [High-dose chemotherapy in ovarian adenocarcinoma].

  Lotz JP, Lhommé C, Pautier P, Couteau C, Gligorov J, Alexandre J, Selle F, Izrael V, Maraninchi D, Viens P. Lotz JP, et al. Bull Cancer. 2000 Jan;87(1):63-9. Bull Cancer. 2000. PMID: 10673633 Review. French. No abstract available.